Vilazodone for Major Depressive Disorder
Start vilazodone at 10 mg once daily with food for 7 days, then increase to 20 mg daily for at least 7 days, with a target dose of 40 mg once daily. This titration schedule minimizes gastrointestinal side effects while achieving therapeutic dosing 1.
Initiation and Titration
The FDA-approved dosing regimen requires administration with food to ensure adequate bioavailability 1. The structured titration is:
- Week 1: 10 mg once daily with food
- Week 2: 20 mg once daily with food
- Week 3 onward: 40 mg once daily with food (target therapeutic dose)
The minimum interval between dose increases is 7 days 1. Taking vilazodone without food significantly reduces absorption and may compromise efficacy 2.
Contraindications
Absolute contraindication: Concurrent use with MAOIs or within 14 days of discontinuing MAOIs 1. This includes both traditional MAOIs and linezolid or intravenous methylene blue due to serotonin syndrome risk.
Critical Warnings and Monitoring
Suicidality (Black Box Warning)
Monitor all patients within 1-2 weeks of initiation for increased suicidal thoughts, agitation, irritability, or unusual behavioral changes 3, 1. The risk is highest during the first 1-2 months of treatment, particularly in young adults. This monitoring should continue regularly throughout the acute phase 3.
Screen for Bipolar Disorder
Before initiating vilazodone, screen patients for personal or family history of bipolar disorder, mania, or hypomania 1. Antidepressants can precipitate manic episodes in susceptible individuals 3.
Serotonin Syndrome
Monitor for serotonin syndrome, especially when combining with other serotonergic agents (triptans, tramadol, other antidepressants, St. John's wort). If serotonin syndrome occurs, immediately discontinue vilazodone and all serotonergic agents 1.
Bleeding Risk
Concomitant use with NSAIDs, aspirin, antiplatelet drugs, or anticoagulants increases bleeding risk 1. Consider gastroprotection in high-risk patients.
Treatment Response Assessment
Assess therapeutic response and adverse effects within 1-2 weeks of initiation, then regularly throughout treatment 3. Efficacy data show significant improvement as early as week 1 4.
If inadequate response after 6-8 weeks at target dose, modify treatment 3. This may include switching to a different antidepressant or adding psychotherapy. Response rates to any single antidepressant may be as low as 50% 3.
Treatment Duration
Continue treatment for 4-9 months after achieving satisfactory response in first-episode depression 3. For patients with 2 or more prior episodes, longer maintenance treatment is beneficial 3.
Common Adverse Effects
The most frequent adverse effects (≥5% and twice placebo rate) are 1, 5:
- Diarrhea (28% vs 9% placebo; NNH=6)
- Nausea (23% vs 5% placebo; NNH=6)
- Insomnia (6% vs 2% placebo; NNH=26)
- Vomiting (NNH=30)
Most adverse effects are mild-to-moderate 4, 5. Gastrointestinal symptoms typically improve over time. Discontinuation due to adverse events occurs in approximately 7% of patients in short-term trials 5.
Sexual Dysfunction
Spontaneously reported sexual adverse events occur (NNH=12 vs placebo) 2, though systematically collected rating scale data have not consistently demonstrated treatment-associated sexual dysfunction 6, 5. This represents a potential advantage over some SSRIs 3.
Weight Effects
Short-term trials show no clinically significant weight change 5, 2. In 1-year open-label studies, mean weight increased by 1.7 kg 6, 5.
Drug Interactions
With strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir): Do not exceed 20 mg once daily 1.
With strong CYP3A4 inducers (carbamazepine, phenytoin, rifampin) used >14 days: Consider increasing vilazodone to 80 mg once daily over 1-2 weeks 1.
Discontinuation
When stopping vilazodone, taper the dose gradually rather than abrupt cessation 1. This reduces the risk of discontinuation symptoms.
Special Populations
Angle-closure glaucoma: Avoid in patients with untreated anatomically narrow angles 1.
Pregnancy: Third-trimester use may increase risk for persistent pulmonary hypertension and neonatal withdrawal 1.
Seizure disorders: Use with caution; seizures can occur with treatment 1.
Clinical Context
While vilazodone's dual mechanism (SSRI plus 5-HT1A partial agonist) is theoretically advantageous, no evidence demonstrates superior efficacy compared to other second-generation antidepressants 3, 7. Selection should be based on adverse effect profile, cost, patient preference, and prior treatment response 3, 7. Vilazodone may be considered as a second- or third-line option, particularly when sexual dysfunction or weight gain with other antidepressants is problematic 8.